DILIsym Services Inc. Releases DILIsym® Version 8A

Software: DILIsym®
Division: DILIsym Services

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– DILIsym Services Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released DILIsym® Version 8A, its flagship QST (quantitative systems toxicology) modeling software.

Dr. Paul Watkins, chair of the DILI-sim Scientific Advisory Board, said: “The DILI-sim Initiative input has led to this release of an updated version of the DILIsym tool. DILIsym version 8A includes many new important example compounds and addresses, for the first time, drug-induced injury to bile duct cells. We are confident that the pharmaceutical industry will find these enhancements extremely useful for detecting and understanding DILI (drug-induced liver injury).”

Dr. Brett Howell, president of DILIsym Services, added: “DILIsym v8A is the result of an immense effort by our highly skilled modeling and simulation team and the support of our DILI-sim member companies. DILIsym Services will be hosting a webinar on Thursday, January 24, 2019, to introduce new mechanisms and simulated populations (SimPops®), as well as a host of other exciting new features.” Register for the webinar here.

Enhancements include:

  • 10 New validation compounds
  • New Cholestatic liver injury mechanism
  • New Oxidative stress (ROS) NRF2 adaptation response framework
  • New Human SimPops with variability in bilirubin processing pathways
  • New Liver injury biomarker GLDH
  • Live DILIsym documentation website updated with new training resources
  • Plus much more …

Shawn O’Connor, chief executive officer of DILIsym Services Inc. parent company Simulations Plus, said: “DILIsym Version 8A reaffirms our leadership in QST/QSP modeling and, specifically, the area of drug-induced liver injury. It is an example of how the use of predictive modeling and simulation tools can be used to improve the cost and efficiency of drug development and, importantly, positively support decision making that can directly impact patient safety.”

DILIsym is available to the pharmaceutical and chemical industries for direct use to predict and understand liabilities via membership in the DILI-sim Initiative consortium. Membership fees include two instances of the software per member company, as well as a number of other benefits, such as having a vote in what updates or new features are included in future versions. Software licenses for DILIsym are also available for companies who wish to apply the tool in the absence of consortium membership, along with government agencies and academics. DILIsym Services Inc. also routinely uses DILIsym for comprehensive consulting services on safety-related issues.

Contact us to receive a free trial version today!